Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Exome sequencing directly implicates 68 genes in inflammatory bowel diseaseRuifei Zhu, Qian Zhang, Kai Yuan, et al.
Gynecologic Oncology|June 7, 2025
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysisZhuxuan Fu, Lauren Borho, Sarah E Taylor, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastasesNicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
Mayo Clinic Proceedings|March 6, 2018
MyD88 and TLR4 Expression in Epithelial Ovarian CancerMatthew S Block, Robert A Vierkant, Peter F Rambau, et al.
British Journal of Cancer|June 20, 2020
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis ConsortiumFilipe Correia Martins, Dominique-Laurent Couturier, Anna Paterson, et al.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
The Journal of Pathology. Clinical Research|August 1, 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium studyPeter F Rambau, Robert A Vierkant, Maria P Intermaggio, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Pageof 9